PharmaEngine (4162.TWO) Stock Price

PharmaEngine Price

🇹🇼CLOSED
57.30TWD
Market closed
Today +/-
Today %

PharmaEngine (4162.TWO) Stock | ISIN TW0004162003. The current PharmaEngine stock price is 57.3 TWD (2026). Revenue is 972.32 M TWD. Net income is 414.14 M TWD. The P/E ratio is 19.91. Market capitalization is 8.35 B TWD. PharmaEngine operates in the Health sector.

Over the last 13 years PharmaEngine grew revenue by 17.2% annually, reaching 2.52 B TWD. Earnings per share have grown at 12.2% per year over the last 13 years. For PharmaEngine, the net margin of 69.4% is up versus 57.2% a few years ago. At today's price the dividend yield works out to roughly 2.62%. The payout ratio is around 122% of earnings.

PharmaEngine stock price

Ex-Dividend
Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of PharmaEngine over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how PharmaEngine stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing PharmaEngine's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

PharmaEngine Stock Price History
DatePharmaEngine Price
Access this data via the Eulerpool API

PharmaEngine Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2008
0 TWD
-137.4 M TWD
-114.77 M TWD
Jan 1, 2009
0 TWD
-106.25 M TWD
-98.7 M TWD
Jan 1, 2010
0 TWD
-91.96 M TWD
-48.15 M TWD
Jan 1, 2011
320.05 M TWD
242.32 M TWD
285.71 M TWD
Jan 1, 2012
184.03 M TWD
49.63 M TWD
48.99 M TWD
Jan 1, 2013
37.4 M TWD
-139.48 M TWD
-117.85 M TWD
Jan 1, 2014
228.99 M TWD
70.55 M TWD
123.59 M TWD
Jan 1, 2015
507.24 M TWD
327.33 M TWD
394.02 M TWD
Jan 1, 2016
1.13 B TWD
808.12 M TWD
689.63 M TWD
Jan 1, 2017
853.68 M TWD
612.97 M TWD
387.06 M TWD
Jan 1, 2018
293.43 M TWD
42.44 M TWD
129.36 M TWD
Jan 1, 2019
314.04 M TWD
32.61 M TWD
42.55 M TWD
Jan 1, 2020
1.06 B TWD
809.71 M TWD
604.28 M TWD
Jan 1, 2021
654.84 M TWD
362.69 M TWD
426.03 M TWD
Jan 1, 2022
654.38 M TWD
282.74 M TWD
318.78 M TWD

PharmaEngine Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jun 16, 2026, 5:10 AM
 
REVENUE (B TWD)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (B TWD)
NET INCOME (B TWD)
NET INCOME GROWTH (%)
DIV. (TWD)
DIV. GROWTH (%)
SHARES (M)
DOCUMENTS
2019202020212022202320242025e2026e
0.311.060.650.650.772.520.90.97
7.17236.31-38.0717.28228.94-64.418.24
89.8196.494.3492.3593.6198.1275.61254.63
0.281.020.620.60.722.482.482.48
0.040.60.430.320.271.750.380.41
-67.441,338.1-29.47-25.35-13.84539.05-78.188.38
---2.721.563.46
-25.93-25300-42.33
145.73145.9144.74143.7143.74143.93143.93143.93
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales PharmaEngine generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue PharmaEngine retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare PharmaEngine's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares PharmaEngine has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against PharmaEngine's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

PharmaEngine stock margins

The PharmaEngine margin analysis displays the gross margin, EBIT margin, as well as the profit margin of PharmaEngine. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for PharmaEngine.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2008
98.11 %
- %
- %
Jan 1, 2009
98.11 %
- %
- %
Jan 1, 2010
98.11 %
- %
- %
Jan 1, 2011
97.4 %
75.71 %
89.27 %
Jan 1, 2012
93.3 %
26.97 %
26.62 %
Jan 1, 2013
45.93 %
-372.95 %
-315.1 %
Jan 1, 2014
96.94 %
30.81 %
53.97 %
Jan 1, 2015
98.65 %
64.53 %
77.68 %
Jan 1, 2016
99.82 %
71.21 %
60.77 %
Jan 1, 2017
99.67 %
71.8 %
45.34 %
Jan 1, 2018
95.61 %
14.46 %
44.09 %
Jan 1, 2019
89.87 %
10.38 %
13.55 %
Jan 1, 2020
96.47 %
76.68 %
57.22 %
Jan 1, 2021
94.34 %
55.39 %
65.06 %
Jan 1, 2022
92.41 %
43.21 %
48.72 %

PharmaEngine Stock Revenue, EBIT, Earnings per Share

The PharmaEngine earnings per share therefore indicates how much revenue PharmaEngine has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2008
0 TWD
-1.26 TWD
-1.05 TWD
Jan 1, 2009
0 TWD
-0.97 TWD
-0.9 TWD
Jan 1, 2010
0 TWD
-0.84 TWD
-0.44 TWD
Jan 1, 2011
3.04 TWD
2.3 TWD
2.71 TWD
Jan 1, 2012
1.45 TWD
0.39 TWD
0.39 TWD
Jan 1, 2013
0.28 TWD
-1.03 TWD
-0.87 TWD
Jan 1, 2014
1.56 TWD
0.48 TWD
0.84 TWD
Jan 1, 2015
3.43 TWD
2.21 TWD
2.66 TWD
Jan 1, 2016
7.7 TWD
5.48 TWD
4.68 TWD
Jan 1, 2017
5.78 TWD
4.15 TWD
2.62 TWD
Jan 1, 2018
1.99 TWD
0.29 TWD
0.88 TWD
Jan 1, 2019
2.15 TWD
0.22 TWD
0.29 TWD
Jan 1, 2020
7.24 TWD
5.55 TWD
4.14 TWD
Jan 1, 2021
4.52 TWD
2.51 TWD
2.94 TWD
Jan 1, 2022
4.55 TWD
1.97 TWD
2.22 TWD

PharmaEngine business model & stock analysis

PharmaEngine, Inc. engages in the research, development and manufacture of biopharmaceutical products. The company is headquartered in Taipei City, Taipei. The company went IPO on 2011-09-01. The firm is developing three new anti-cancer drugs under the brand of ONIVYDE, which are nal-IRI, MM-398 and PEP02. The firm distributes its products mainly to overseas markets,

PharmaEngine Eulerpool Fair Value

PharmaEngine historical P/E ratio, EBIT multiple, and P/S ratio

PharmaEngine annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

PharmaEngine shares outstanding

The number of shares was PharmaEngine in 2025 — This indicates how many shares 143.927 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2008
109.45 M base_Shares
Jan 1, 2009
109.45 M base_Shares
Jan 1, 2010
109.45 M base_Shares
Jan 1, 2011
105.25 M base_Shares
Jan 1, 2012
126.88 M base_Shares
Jan 1, 2013
135.17 M base_Shares
Jan 1, 2014
147.19 M base_Shares
Jan 1, 2015
147.99 M base_Shares
Jan 1, 2016
147.41 M base_Shares
Jan 1, 2017
147.76 M base_Shares
Jan 1, 2018
147.6 M base_Shares
Jan 1, 2019
145.73 M base_Shares
Jan 1, 2020
145.9 M base_Shares
Jan 1, 2021
144.74 M base_Shares
Jan 1, 2022
143.7 M base_Shares

PharmaEngine Dividend History

4 years of dividend payments

YearAnnual DividendYoY ChangePayments
20256TWD 300.0%
Aug 13, 20256TWD 300.0%1/1
20241.5TWD 25.0%
20232TWD 25.9%
20222.7TWD

PharmaEngine dividend history and estimates

In 2025, PharmaEngine paid a dividend amounting to 6 TWD. Dividend means that PharmaEngine distributes a portion of its profits to its owners.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2022
2.7 TWD
0 TWD
Jan 1, 2023
2 TWD
0 TWD
Jan 1, 2024
1.5 TWD
0 TWD
Jan 1, 2025
6 TWD
0 TWD
Invalid Date
0 TWD
3.46 TWD

PharmaEngine dividend payout ratio

In 2025, PharmaEngine had a payout ratio of 121.62%. The payout ratio indicates the percentage of the company's profits that PharmaEngine distributes as dividends.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2008
121.62 %
Jan 1, 2009
121.62 %
Jan 1, 2010
121.62 %
Jan 1, 2011
121.62 %
Jan 1, 2012
121.62 %
Jan 1, 2013
121.62 %
Jan 1, 2014
121.62 %
Jan 1, 2015
121.62 %
Jan 1, 2016
121.62 %
Jan 1, 2017
121.62 %
Jan 1, 2018
121.62 %
Jan 1, 2019
121.62 %
Jan 1, 2020
121.62 %
Jan 1, 2021
121.62 %
Jan 1, 2022
121.62 %
Price targets and forecasts for PharmaEngine are not yet available.

PharmaEngine Earnings Estimates

PharmaEngine Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
4/25/20240.57TWD185.4 MTWD2024 Q1
2/29/20240.47TWD191.58 MTWD2023 Q4

PharmaEngine shareholder structure

% Name
17.75604%
TTY Biopharm Company Limited
TTY Biopharm Company Limited
15.50384%
National Development Fund, Executive Yuan
National Development Fund, Executive Yuan
2.2165%
Zeng (Bao Qing)
Zeng (Bao Qing)
1.91589%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
0.99327%
Yeh (Chang Ching)
Yeh (Chang Ching)
0.8855%
TransGlobe Life Insurance Inc.
TransGlobe Life Insurance Inc.
0.33292%
Dimensional Fund Advisors, L.P.
Dimensional Fund Advisors, L.P.
0.28747%
Norges Bank Investment Management (NBIM)
Norges Bank Investment Management (NBIM)
0.07894%
Dimensional Fund Advisors, Ltd.
Dimensional Fund Advisors, Ltd.
0.06109%
American Century Investment Management, Inc.
American Century Investment Management, Inc.

PharmaEngine Executives and Management Board

JH

Mr. Jan-Yau Hsu

Chairman of the Board · since 2022

Compensation4.52 M TWD
CL

Mr. Chien-Huang Lin

Independent Director

Compensation1.68 M TWD
MH

Mr. Ming-Feng Hou

Director

Compensation1.26 M TWD
WH

Ms. Wen-Hung Hsu

Director

Compensation84,000 TWD
MW

Mr. Ming-Shiang Wu

Director

Compensation84,000 TWD

Frequently asked questions about PharmaEngine

All fundamentals and in-depth analysis of PharmaEngine

Our stock analysis for PharmaEngine Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PharmaEngine Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.